![Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised,](https://www.thelancet.com/cms/asset/88218c63-d7e9-48e5-8e97-b05397e8dddd/gr1.jpg)
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised,
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://www.thelancet.com/cms/asset/643af9b2-1d35-4487-bda0-687f2e80ab01/gr1.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![DCGI approves market authorisation for Covovax as heterologous booster dose - The Hindu BusinessLine DCGI approves market authorisation for Covovax as heterologous booster dose - The Hindu BusinessLine](https://bl-i.thgim.com/public/news/lg97gf/article66294022.ece/alternates/FREE_1200/covid%20vaccine%20hhh.jpg)
DCGI approves market authorisation for Covovax as heterologous booster dose - The Hindu BusinessLine
![Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study - Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study -](https://www.thelancet.com/cms/attachment/33fc2561-e424-4f6f-8c0d-1f997fcb6709/gr1.jpg)
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study -
![Ministry of Health on Twitter: "#LargestVaccineDrive ➡️Schedule for 'precaution' dose of Covid-19 released today. ➡️More than 79 lakh Vaccine doses administered today till 7 pm. https://t.co/e0AS4pl7Mb" / Twitter Ministry of Health on Twitter: "#LargestVaccineDrive ➡️Schedule for 'precaution' dose of Covid-19 released today. ➡️More than 79 lakh Vaccine doses administered today till 7 pm. https://t.co/e0AS4pl7Mb" / Twitter](https://pbs.twimg.com/media/FIltM6OUUAEDG8v.jpg)